Skip to main content

Table 9 The combined synergizing effects of Mcl1-inhibitors against selected cancer and cell types

From: BH3-mimetics: recent developments in cancer therapy

Agents Cancer Cell Type Combined Ref
A1210477 AML THP-1 U937 venetoclax [337]
A1210477 Breast MDA-MB-231 cells TRAIL [338]
A1210477 Cervical SiHa and CaSki navitoclax [139]
A1210477 CML K562, K562/R EE-84 [339]
A1210477 CRC RKO, HT29, A375 cobimetinib [340]
A1210477 DLBCL U-2946 navitoclax [341]
A1210477 PC, GC, NSCLC, MM BxPC-3, EJ-1, H23, and OPM-2 navitoclax [70]
A1210477 HNSCC PCI15B, Detroit 562, MDA686LN, and HN30 navitoclax [342]
A1210477 nHL SU-DHL-4, WSU-NHL, WSU-DLCL2, KARPAS-422 venetoclax [343]
AMG-176 CLL Patient samples (5) venetoclax [344]
AZD-5991 AML OCI-AML3 and MCL-1-OE Molm13 and MV4–11 venetoclax [345]
AZD5991 MM NCI-H929 bortezomib, venetoclax [73]
GDC-0941 Breast MDA-MB-231, SKBR3 ABT-737 [346]
Mim1 Glioblastoma U87mg temozolomide [347]
Mim1 Melanoma C32 melanoma cells dacarbazine [348]
Mim1 MM Colo829 dacarbazine [349]
S63845 AML OCI-AML3, MOLM-13, OCI-AML2 trametinib/HDM201 [350]
S63845 AML Primary samples venetoclax [351]
S63845 AML MOML-13, SKM-1, trametinib [352]
S63845 AML Cell lines and primary cells venetoclax [353]
S63845 Breast SK-BR-3 docetaxel, trastuzumab, lapatinib [354]
S63845 CRC HCT116 regorafenib [355]
S63845 Mantle cell lymphoma Patient-derived xenografts venetoclax [356]
S63845 Melanoma Patient samples navitoclax [357]
S63845 Melanoma MeWo TRAIL resistance [358]
S63845 Myeloma U266 xenograft venetoclax [359]
S63845 MM MOL-P8, OPM-2, NCI-H929 venetoclax, bortezomib [360]
S63845 MM RPMI-8226 xenograft venetoclax [361]
S63845 Nasopharyngeal carcinoma CNE-2, 5-8F venetoclax [293]
S63845 T-ALL Zebrafish T-ALL cells venetoclax [304]
VU661013 AML MV-4-11, AML-001/2, patient xenografts venetoclax [76]
VU661013 Breast HCC1428, MCF7, T47D navitoclax [362]
  1. The therapeutic types (Agents) are highlighted in bold (left column) and their corresponding studies referenced in the column on the right (Ref). Abbreviations: CML Chronic Myelogenous Leukemia, CRC Colorectal cancer, DLBCL Diffuse large B-Cell Lymphoma, PC Prostate Cancer, GC Gastric Cancer, NSCLC Non-small cell lung cancer, MM Multiple myeloma, HNSCC Head and Neck Squamous Cell Carcinoma, nHL Non-Hodgkin’s Lymphoma, CLL Chronic lymphocytic leukemia, AML Acute Myelogenous Lymphoma, T-ALL T-cell acute lymphoblastic leukemia
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us